RNA Technologies and Therapeutics
RNA Technologies and Therapeutics Inc. (RNA T&T) provides custom design, optimization, and small-to-mid-scale production of in vitro transcribed RNA, including nucleoside-modified mRNAs and long non-coding RNAs, for therapeutic development. The company offers sequence and UTR engineering, plus encapsulation in lipid nanoparticles for targeted delivery, serving biotech and academic partners in vaccine development, gene therapy, and stem cell reprogramming.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Developing mRNA-based therapeutics is significantly more challenging than creating mRNA vaccines, with hurdles related to delivery, safety, and duration of protein expression. Researchers and biotech companies also face infrastructural barriers in accessing high-quality RNA and targeted delivery systems needed to advance clinical and translational research in areas like vaccine development, gene therapy, and stem cell reprogramming.
Solution
RNA Technologies and Therapeutics Inc. (RNA T&T) addresses these challenges by providing design, optimization, and small-to-mid-scale production (mg to g) of in vitro transcribed RNA, including nucleoside-modified mRNAs and long non-coding RNAs. The company offers customized sequence and codon optimization, UTR engineering for improved translation efficiency, and encapsulation in commercially available lipid nanoparticles (LNPs) or hybrid delivery systems. RNA T&T produces RNA ranging from a few hundred nucleotides up to 5,000 nucleotides, with the ability to generate hundreds of sequence variants for rapid screening in therapeutic applications. The company's goal is to become a leader in mRNA engineering and targeted therapeutics by delivering optimized, high-quality RNA and delivery solutions to its partners in biotech and academia.
Target Audience
Primary customers are biotech companies and academic research partners in need of high-quality in vitro transcribed RNA and targeted lipid-based delivery systems for vaccine development, gene therapy, stem cell reprogramming, and other non-viral gene therapy applications.
Features
- Custom RNA synthesis from ~100 to 5,000 nucleotides, including mRNA and lncRNA
- Hundreds of sequence variants can be produced for rapid therapeutic screening
- Codon and sequence optimization for enhanced protein expression
- UTR optimization to improve translation efficiency
- Encapsulation in commercially available LNPs and targeted lipid-based hybrid delivery systems
- Comprehensive quality control: Bioanalyzer integrity testing, sequencing for transcription identity, dot immunoblots for dsRNA removal, dynamic light scattering for LNP size, Ribogreen assay for encapsulation efficiency and concentration, and pH, osmolarity, and surface charge measurements